Cargando…

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice

Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamai, Takuo, Ikezawa, Kenji, Kawamoto, Yasuharu, Hirao, Takeru, Higashi, Sena, Daiku, Kazuma, Maeda, Shingo, Abe, Yutaro, Urabe, Makiko, Kai, Yugo, Takada, Ryoji, Nakabori, Tasuku, Uehara, Hiroyuki, Ohkawa, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026505/
https://www.ncbi.nlm.nih.gov/pubmed/35448190
http://dx.doi.org/10.3390/curroncol29040216
_version_ 1784691139699277824
author Yamai, Takuo
Ikezawa, Kenji
Kawamoto, Yasuharu
Hirao, Takeru
Higashi, Sena
Daiku, Kazuma
Maeda, Shingo
Abe, Yutaro
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Nakabori, Tasuku
Uehara, Hiroyuki
Ohkawa, Kazuyoshi
author_facet Yamai, Takuo
Ikezawa, Kenji
Kawamoto, Yasuharu
Hirao, Takeru
Higashi, Sena
Daiku, Kazuma
Maeda, Shingo
Abe, Yutaro
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Nakabori, Tasuku
Uehara, Hiroyuki
Ohkawa, Kazuyoshi
author_sort Yamai, Takuo
collection PubMed
description Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17 patients with UR-PC who initiated 5-FU/l-LV plus oxaliplatin (FOLFOX) as salvage chemotherapy at our hospital between June 2020 and August 2021, after treatment with GnP and 5-FU/LV plus nal-IRI. The primary endpoint was tumor response. The secondary endpoints were progression-free survival (PFS) and adverse events (AEs). The response and disease control rates were 5.9% (1/17) and 17.6% (3/17), respectively. The median PFS was 1.8 months (range: 0.4–5.2 months). Eight patients (47.1%) experienced grade 3 nonhematologic AEs, while none experienced grade 3 hematologic AEs. Two patients with controlled disease had homologous recombination deficiency (HRD)-associated gene mutations in cancer panel testing. The FOLFOX regimen benefit for UR-PC patients treated with GnP and 5-FU/LV plus nal-IRI may be limited to patients with HRD-associated gene mutations.
format Online
Article
Text
id pubmed-9026505
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90265052022-04-23 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice Yamai, Takuo Ikezawa, Kenji Kawamoto, Yasuharu Hirao, Takeru Higashi, Sena Daiku, Kazuma Maeda, Shingo Abe, Yutaro Urabe, Makiko Kai, Yugo Takada, Ryoji Nakabori, Tasuku Uehara, Hiroyuki Ohkawa, Kazuyoshi Curr Oncol Communication Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17 patients with UR-PC who initiated 5-FU/l-LV plus oxaliplatin (FOLFOX) as salvage chemotherapy at our hospital between June 2020 and August 2021, after treatment with GnP and 5-FU/LV plus nal-IRI. The primary endpoint was tumor response. The secondary endpoints were progression-free survival (PFS) and adverse events (AEs). The response and disease control rates were 5.9% (1/17) and 17.6% (3/17), respectively. The median PFS was 1.8 months (range: 0.4–5.2 months). Eight patients (47.1%) experienced grade 3 nonhematologic AEs, while none experienced grade 3 hematologic AEs. Two patients with controlled disease had homologous recombination deficiency (HRD)-associated gene mutations in cancer panel testing. The FOLFOX regimen benefit for UR-PC patients treated with GnP and 5-FU/LV plus nal-IRI may be limited to patients with HRD-associated gene mutations. MDPI 2022-04-11 /pmc/articles/PMC9026505/ /pubmed/35448190 http://dx.doi.org/10.3390/curroncol29040216 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Yamai, Takuo
Ikezawa, Kenji
Kawamoto, Yasuharu
Hirao, Takeru
Higashi, Sena
Daiku, Kazuma
Maeda, Shingo
Abe, Yutaro
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Nakabori, Tasuku
Uehara, Hiroyuki
Ohkawa, Kazuyoshi
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
title 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
title_full 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
title_fullStr 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
title_full_unstemmed 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
title_short 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
title_sort 5-fluorouracil/l-leucovorin plus oxaliplatin (folfox) regimen as salvage chemotherapy for patients with unresectable pancreatic cancer receiving gemcitabine and nab-paclitaxel and 5-fluorouracil/l-leucovorin plus nanoliposomal irinotecan: preliminary results from clinical practice
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026505/
https://www.ncbi.nlm.nih.gov/pubmed/35448190
http://dx.doi.org/10.3390/curroncol29040216
work_keys_str_mv AT yamaitakuo 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT ikezawakenji 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT kawamotoyasuharu 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT hiraotakeru 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT higashisena 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT daikukazuma 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT maedashingo 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT abeyutaro 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT urabemakiko 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT kaiyugo 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT takadaryoji 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT nakaboritasuku 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT ueharahiroyuki 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice
AT ohkawakazuyoshi 5fluorouracillleucovorinplusoxaliplatinfolfoxregimenassalvagechemotherapyforpatientswithunresectablepancreaticcancerreceivinggemcitabineandnabpaclitaxeland5fluorouracillleucovorinplusnanoliposomalirinotecanpreliminaryresultsfromclinicalpractice